Deutsche Märkte öffnen in 6 Stunden 45 Minuten

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
112,91+0,21 (+0,19%)
Börsenschluss: 04:00PM EDT
114,01 +1,10 (+0,97%)
Nachbörse: 05:42PM EDT

Jazz Pharmaceuticals plc

Waterloo Exchange
Fifth Floor Waterloo Road
Dublin D04 E5W7
Ireland
353 1 634 7800
https://www.jazzpharma.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter2.800

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Bruce C. CozaddCo-Founder, Chairman & CEO2,44MN/A1964
Ms. Renee D. GalaPresident & COO1,36MN/A1972
Ms. Patricia CarrSenior VP & Chief Accounting Officer633,4kN/A1971
Ms. Neena M. Patil J.D.Executive VP & Chief Legal Officer1,01MN/A1975
Dr. Robert Iannone M.D.Executive VP and Global Head of Research & Development1,19MN/A1967
Mr. Philip L. JohnsonExecutive VP & CFON/AN/A1964
Ms. Andrea N. Flynn Ph.D.VP & Head of Investor RelationsN/AN/AN/A
Ms. Heidi MannaExecutive VP & Chief People OfficerN/AN/A1972
Dr. Jed Black M.D.Senior Vice President of Sleep & CNS MedicineN/AN/AN/A
Ms. Samantha PearceSenior Vice President of Europe & InternationalN/AN/A1966
Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Corporate Governance

Jazz Pharmaceuticals plcs ISS Governance QualityScore, Stand 1. Juni 2024, lautet 3. Die grundlegenden Scores sind Audit: 8, Vorstand: 3, Shareholderrechte: 3, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.